Effect of Dexamethasone on Days Alive, Ventilator-Free in Patients With COVID-19, Acute Respiratory Distress Syndrome

JAMA

EMBARGOED FOR RELEASE: 10 A.M. (ET), WEDNESDAY, SEPTEMBER 2, 2020

Media advisory: The full study and editorial are linked to this news release. A visual abstract is below. This study is being published to coincide with the release of guidelines from the World Health Organization regarding use of corticosteroids for treatment of critically ill COVID-19 patients.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17021?guestAccessKey=52805eb1-785a-4bcc-8d1d-9ca94a382711&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090220

 

What The Study Did: This randomized clinical trial in Brazil of 299 patients with COVID-19 and moderate or severe acute respiratory distress syndrome (ARDS) examined if intravenous dexamethasone plus standard care compared with standard care alone would increase the number of days patients were alive and free from mechanical ventilation.

Authors: Luciano C. P. Azevedo, M.D., Ph.D., of Hospital Sirio-Libanes in São Paulo, Brazil, is the corresponding author.

 

Visual Abstract

(doi:10.1001/jama.2020.17021)

Editor’s Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.